Complications of a lung biopsy for severe respiratory failure : A systematic review and meta-analysis
Copyright © 2022 [The Author/The Authors]. Published by Elsevier B.V. All rights reserved..
BACKGROUND: This systematic review and meta-analysis aimed to evaluate the complications of lung biopsy in patients with acute respiratory failure (ARF), including acute respiratory distress syndrome (ARDS).
METHODS: We searched the MEDLINE and Cochrane Central Register of Controlled Trials. The primary outcomes were biopsy-related death, respiratory failure, cardiac complications, bleeding, and other major complications. We used the McMaster Quality Assessment Scale of Harms (McHarm) to evaluate the risk of bias. A random-effects model was used to calculate the pooled frequencies.
RESULTS: Thirteen studies (consisting of 574 patients) were included in the meta-analysis. Furthermore, most of the included studies had a high or unclear risk of bias in half of the items in McHarm. All included studies evaluated surgical lung biopsies. The median overall hospital mortality was 53% (range: 17%-90%). The pooled frequencies of biopsy-related death, respiratory failure, cardiac complication, bleeding, and other major complications were 0.00% (95% confidence interval [CI]: 0.00%-0.21%), 1.30% (95% CI: 0.00%-5.69%), 1.03% (95% CI: 0.00%-3.73%), 1.46% (95% CI: 0.16%-3.56%), and 4.26% (95% CI: 0.00%-13.0%), respectively.
CONCLUSIONS: The results of this study will be valuable information in considering the indications of lung biopsy in patients with ARF, including ARDS.
TRIAL REGISTRATION: The protocol was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN 000040650).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Respiratory investigation - 61(2023), 1 vom: 01. Jan., Seite 121-132 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sugimoto, Hiroshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome (ARDS) |
|---|
| Anmerkungen: |
Date Completed 12.01.2023 Date Revised 24.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.resinv.2022.08.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346793750 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346793750 | ||
| 003 | DE-627 | ||
| 005 | 20231226032309.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.resinv.2022.08.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346793750 | ||
| 035 | |a (NLM)36163164 | ||
| 035 | |a (PII)S2212-5345(22)00120-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sugimoto, Hiroshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complications of a lung biopsy for severe respiratory failure |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2023 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 [The Author/The Authors]. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: This systematic review and meta-analysis aimed to evaluate the complications of lung biopsy in patients with acute respiratory failure (ARF), including acute respiratory distress syndrome (ARDS) | ||
| 520 | |a METHODS: We searched the MEDLINE and Cochrane Central Register of Controlled Trials. The primary outcomes were biopsy-related death, respiratory failure, cardiac complications, bleeding, and other major complications. We used the McMaster Quality Assessment Scale of Harms (McHarm) to evaluate the risk of bias. A random-effects model was used to calculate the pooled frequencies | ||
| 520 | |a RESULTS: Thirteen studies (consisting of 574 patients) were included in the meta-analysis. Furthermore, most of the included studies had a high or unclear risk of bias in half of the items in McHarm. All included studies evaluated surgical lung biopsies. The median overall hospital mortality was 53% (range: 17%-90%). The pooled frequencies of biopsy-related death, respiratory failure, cardiac complication, bleeding, and other major complications were 0.00% (95% confidence interval [CI]: 0.00%-0.21%), 1.30% (95% CI: 0.00%-5.69%), 1.03% (95% CI: 0.00%-3.73%), 1.46% (95% CI: 0.16%-3.56%), and 4.26% (95% CI: 0.00%-13.0%), respectively | ||
| 520 | |a CONCLUSIONS: The results of this study will be valuable information in considering the indications of lung biopsy in patients with ARF, including ARDS | ||
| 520 | |a TRIAL REGISTRATION: The protocol was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN 000040650) | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute respiratory distress syndrome (ARDS) | |
| 650 | 4 | |a Acute respiratory failure | |
| 650 | 4 | |a Complications | |
| 650 | 4 | |a Lung biopsy | |
| 700 | 1 | |a Fukuda, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Yoshie |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Takuo |e verfasserin |4 aut | |
| 700 | 1 | |a Okamori, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ando, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Yohei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory investigation |d 2012 |g 61(2023), 1 vom: 01. Jan., Seite 121-132 |w (DE-627)NLM217493343 |x 2212-5353 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:121-132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.resinv.2022.08.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 1 |b 01 |c 01 |h 121-132 | ||